Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity.

Author: StahlStephen M

Paper Details 
Original Abstract of the Article :
Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies target...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1017/S1092852919001470

データ提供:米国国立医学図書館(NLM)

Dextromethorphan/Bupropion: A Novel Approach to Depression Treatment

This research explores the potential of dextromethorphan/bupropion, a novel combination of existing drugs, as a treatment for major depressive disorder (MDD). The combination targets the NMDA (N-methyl-d-aspartate) receptor, a key player in brain function and mood regulation. The authors suggest that this combination could offer a faster and more effective treatment option for MDD, addressing the limitations of current antidepressant therapies. The research highlights the need for new treatment approaches for MDD, particularly for patients who do not respond well to traditional therapies.

Dextromethorphan/Bupropion: A Potential Breakthrough in Depression Treatment

This research offers a promising new approach to treating MDD, a debilitating mental illness. The combination of dextromethorphan and bupropion, targeting the NMDA receptor, could potentially offer a faster and more effective treatment option for individuals with MDD. The study's findings highlight the need for new treatment strategies that address the limitations of traditional therapies, offering hope for a more effective approach to managing MDD.

Depression: A Complex Landscape Seeking New Solutions

Depression, a complex and often debilitating mental illness, affects millions of individuals worldwide. This research sheds light on a potential new treatment approach, targeting the NMDA receptor, which could potentially offer a faster and more effective alternative to existing therapies. It's like discovering a hidden oasis in the desert of depression, offering a source of relief and hope for individuals seeking a more effective treatment.

Dr. Camel's Conclusion

This research offers a refreshing perspective on treating depression, exploring a new path through the desert of mental illness. The combination of dextromethorphan/bupropion, targeting the NMDA receptor, holds promise for a faster and more effective treatment option for individuals struggling with MDD.

Date :
  1. Date Completed 2020-08-25
  2. Date Revised 2021-05-10
Further Info :

Pubmed ID

31566163

DOI: Digital Object Identifier

10.1017/S1092852919001470

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.